> The panel on Thursday recommended the manufacturing and sales of two iPS cell-derived products on condition that the two developers conduct studies involving all treated patients and further verify the efficacy and safety of their respective products within seven years.
> Cuorips, a startup originating from the University of Osaka, developed cardiomyocyte sheets for treating ischemic cardiomyopathy, a serious heart disease.
Sumitomo Pharma submitted an application involving cells for transplantation into the brains of patients with Parkinson's disease, which causes symptoms including tremors in the limbs.
> The two companies had applied to manufacture and market the products last year.
> The panel on Thursday recommended the manufacturing and sales of two iPS cell-derived products on condition that the two developers conduct studies involving all treated patients and further verify the efficacy and safety of their respective products within seven years.
> Cuorips, a startup originating from the University of Osaka, developed cardiomyocyte sheets for treating ischemic cardiomyopathy, a serious heart disease. Sumitomo Pharma submitted an application involving cells for transplantation into the brains of patients with Parkinson's disease, which causes symptoms including tremors in the limbs.
> The two companies had applied to manufacture and market the products last year.